Arrowhead Pharmaceuticals’ Post

GLP-1 receptor agonists are reshaping the obesity and diabetes landscape. In 2023, alone, we saw a 352% rise in their prescriptions. Avalere Health talked with #hepatology experts at IHEP (International Hepatology Education Program) to ask what the impact could be for #metabolicdysfunction-associated #steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth, #Hepatology, #MedicalInnovation, #MASH, #NASH, #NAFLD, #GLP1

Currently, there is no cure for PKD other than renal #transplantation (Dennis et al., 2023). #Tolvaptan is the only drug approved by FDA proven to slow eGFR decline in ADPKD patients at the risk of rapid disease progression. Widespread use of tolvaptan is limited by the substantial #aquaretic effects that it produces and by the potential for #liver toxicity (Zhou and Torres, 2023). Recent advances in understanding the #pathophysiology of PKD have led to new approaches to treatment via targeting different signaling #pathways (Zhou and Torres, 2023).

Over the past few decades, the science behind advanced treatments for immune-mediated inflammatory diseases like psoriasis has continually progressed and evolved to address unmet needs for patients. Our deep understanding of immune-mediated diseases and the IL-23 pathway means we are at the forefront of developing targeted treatment options that offer more patients the opportunity to achieve deep and lasting responses.   New data from a Phase 2b study published in the New England Journal of Medicine offer us insight on an investigational targeted oral therapy for people living with moderate-to-severe psoriasis.     https://bit.ly/487peT9     #Psoriasis #JNJImmunology 

Up front & free to read in our Feb issue #editorspicks: Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention tinyurl.com/3cpp2xzx

GLP-1 receptor agonists are showing promising new applications beyond diabetes management. First the boom on Obesity. Also, recent findings suggest potential benefits in areas such as neuroprotection, cardiovascular health, and even substance use disorders. These discoveries could significantly expand the therapeutic scope of GLP-1 receptor agonists, offering new hope for patients with a variety of conditions. #offlabel #repurposing #drugdiscovery #drugdevelopment

𝐒𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐒𝐡𝐨𝐰𝐬 𝐏𝐫𝐨𝐦𝐢𝐬𝐞 𝐢𝐧 𝐑𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐃𝐞𝐚𝐭𝐡 𝐑𝐢𝐬𝐤 𝐟𝐨𝐫 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐊𝐢𝐝𝐧𝐞𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 Novo Nordisk's Novo Nordisk Phase III FLOW trial revealed that semaglutide, a GLP-1 receptor agonist, significantly reduced the risk of death by 20% in type 2 diabetes patients with chronic kidney disease (CKD). Results, presented at the 61st European Renal Association congress and published in The New England Journal of Medicine, also demonstrated a 24% lower likelihood of kidney failure, deterioration in kidney function, or kidney-related/cardiovascular death with semaglutide versus placebo. Semaglutide, mimicking the GLP-1 hormone, promotes insulin secretion and suppresses appetite. Approved as Ozempic for type 2 diabetes and Wegovy for weight management, its label recently expanded to reduce cardiovascular risk in overweight/obese adults with cardiovascular disease. The Phase III FLOW trial, stopped early for efficacy, showcased semaglutide's effectiveness in curbing kidney disease progression and cardiovascular events. Novo plans to seek label expansion for semaglutide to cover CKD this year. #DiabetesResearch #ChronicKidneyDisease #Semaglutide #GLP1Agonist #CardiovascularHealth #MedicalBreakthrough #ClinicalTrials #Endocrinology #Type2Diabetes #Wegovy #Ozempic #NovoNordisk #MedicalScience

The role of plasma angiotensin-converting enzyme and interleukin-6 levels on the prognosis of non-dialysis chronic kidney disease patients. https://ow.ly/sXhf50Qx3tg #Pharmacy #Pharmacology #NaturalProduct #Hypertension

We are pleased to announce the publication of a new subgroup analysis of a long-term, open label study of a CGRP receptor antagonist in patients using preventive migraine medications. Click the link below to read the article #headachemedicine

🔴 Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia https://lnkd.in/eYnuGz4s BACKGROUND • Mixed hyperlipidemia increases risk of atherosclerotic cardiovascular disease. • Elevated non-HDL cholesterol is driven by remnant cholesterol in triglyceride-rich lipoproteins. • APOC3 inhibits lipoprotein lipase, reducing metabolism and clearance of these lipoproteins. METHODS • 48-week, phase 2b, double-blind, randomized, placebo-controlled trial. • 353 patients with mixed hyperlipidemia. • Participants received plozasiran (10 mg, 25 mg, or 50 mg) or placebo, quarterly or half-yearly. • Primary endpoint: percent change in fasting triglycerides at week 24. RESULTS • Significant triglyceride reductions with plozasiran (range: -44.2 to -62.4 percentage points). • Worsening glycemic control: 7% to 21% in plozasiran groups vs. 10% with placebo. CONCLUSIONS • Plozasiran significantly reduced triglyceride levels. • Further clinical trials are needed to assess long-term outcomes. @Endocrinology_and_Diabetes

Trial of Lixisenatide in Early Parkinson’s Disease Lixisenatide is a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes. In participants with early #Parkinson’s disease, #lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson’s disease. #GLP-1 #pharmacology #medicines